The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Neurotrope, Inc. Investors and a Lead Plaintiff Deadline of July 17, 2017 (NTRP)

The Klein Law Firm reveals that a class action grievance has actually been submitted on behalf of investors of Neurotrope, Inc. (NASDAQ: NTRP) who bought shares in between January 7, 2016, and April 28, 2017. The action, which was submitted in the United States District Court for the Southern District of New York, declares that the Company broke federal securities laws.

The problem declares that throughout the Class Period Neurotrope released materially incorrect and deceptive declarations and/or cannot reveal product details worrying the effectiveness of its lead item prospect, Bryostatin-1. On May 1, 2017, Neurotrope provided a news release revealing “favorable top-line outcomes” of the critical Phase 2b trials of Bryostatin-1, keeping in mind “enhancement in clients with moderate to serious Alzheimer’s illness.” Nevertheless, the underlying trial information opposes these representations, as the top-line information connecting to the 20 microgram dosage of Bryostatin-1 cannot produce outcomes that were statistically substantial. In addition, Neurotrope cannot divulge declarations relating to the effectiveness of the 40 microgram dosage with regard to its main and secondary endpoints. Upon this news, shares of Neurotrope fell from a close of $18.81 on April 28, 2017, to a close of $6.97 per share on May 1, 2017.

Investors have up until July 17, 2017, to petition the court for lead complainant status. Your capability to share in any recovery does not need that you act as the lead complainant. You might decide to be a missing class member.